Life insurance blood tests are not designed to detect cancer, and they won’t screen for it directly. These tests look for common health risks like diabetes, high cholesterol, and liver problems. However, certain cancers can cause abnormalities in the same markers insurers measure, which means a life insurance blood draw could indirectly raise a red flag that leads to further investigation.
What Life Insurance Blood Tests Actually Measure
The blood panel used for life insurance underwriting is a general health screening, not a diagnostic workup. It typically includes cholesterol and triglyceride levels, hemoglobin A1C (a long-term blood sugar marker for diabetes risk), liver enzymes, kidney function markers, and sometimes a complete blood count. Insurers also test for HIV, hepatitis, nicotine, and drug use.
None of these are tumor markers. The insurer isn’t looking for prostate-specific antigen (PSA), cancer antigen 125, or any of the specialized proteins that oncologists use to track malignancies. The goal is to assess your overall mortality risk, primarily from heart disease, diabetes, liver disease, and substance use.
How Cancer Could Still Show Up Indirectly
Even though the tests aren’t cancer-specific, some cancers leave fingerprints on routine blood work. The results won’t say “cancer,” but they can produce numbers that look unusual enough to prompt questions.
White blood cell counts: A complete blood count measures red cells, white cells, and platelets. Blood cancers like leukemia and lymphoma can cause white blood cell counts to spike well above normal ranges. A dramatically abnormal count wouldn’t tell the insurer what’s wrong, but it would signal something is off.
Liver enzymes: Insurers pay close attention to three liver enzymes: AST, ALT, and GGT. A study of life insurance applicants found that elevated GGT is associated not only with liver disease and cardiovascular risk but also with cancer incidence. When GGT alone was elevated, or when both ALT and AST were elevated together, mortality risk climbed significantly. Liver cancers, metastases that have spread to the liver, or bile duct obstructions from a tumor can all push these numbers higher.
Total protein and globulin: Some panels include a total protein measurement. Abnormally high total protein can be a sign of multiple myeloma, a blood cancer that causes the body to overproduce certain proteins. High globulin levels specifically have been linked to multiple myeloma, Hodgkin disease, and leukemia. These aren’t common findings, but when they appear, they stand out.
Anemia markers: A low red blood cell count can reflect many things, from iron deficiency to chronic disease. But certain cancers, particularly those in the bone marrow or gastrointestinal tract, cause anemia that would show up on a standard blood count.
What Insurers Won’t Catch
The vast majority of cancers, especially early-stage solid tumors like breast, lung, prostate, and colon cancer, will not produce detectable changes on a standard insurance blood panel. These cancers grow locally for months or years before they start affecting blood chemistry in measurable ways. A person with stage 1 breast cancer or a small lung nodule could have perfectly normal blood work across every marker the insurer checks.
Even experimental multi-cancer blood tests developed specifically to find early tumors have limited sensitivity. In one clinical trial studied by the National Cancer Institute, a purpose-built cancer detection blood test missed 22 out of 24 early-stage cancers that standard screening (mammograms, CT scans, colonoscopies) caught instead. These research-grade tests are far more sophisticated than anything used in insurance underwriting, and even they struggle with early detection. A routine insurance panel has essentially no chance of catching an early solid tumor.
What Happens If Results Are Abnormal
An out-of-range result on a life insurance blood test doesn’t automatically mean you’ll be denied coverage, and it certainly doesn’t mean you have cancer. Abnormal results can come from dozens of causes: a recent illness, a heavy meal before the test, medications, dehydration, or simply normal variation.
When something looks unusual, the insurer’s underwriting team typically requests more information. This might include an Attending Physician Statement, which is a report from your doctor summarizing your medical history and any existing diagnoses. If the abnormality is significant, the insurer may ask you to get a recheck through your own physician. The insurance company itself won’t order a biopsy or send you for a CT scan.
If you already have a cancer diagnosis in your medical records, that will surface through the Attending Physician Statement or the medical history questionnaire on your application, not through the blood test. The blood work is a secondary data point, not the primary tool for uncovering a serious condition.
Why This Matters for Applicants
If you’re applying for life insurance and wondering whether the blood test will reveal an undiagnosed cancer, the realistic answer is: almost certainly not, unless you have an advanced blood cancer or a tumor that has already spread enough to disrupt your liver, kidneys, or blood cell production. For the early-stage cancers most people worry about, a standard insurance panel is essentially blind.
That said, if your insurance blood work does come back with unexpected abnormalities, it’s worth following up with your own doctor regardless of what happens with your policy. Elevated liver enzymes, abnormal protein levels, or unusual blood counts deserve a proper medical evaluation, even if the insurer was only interested in them for pricing purposes. Occasionally, people discover a health issue they didn’t know about precisely because an insurance screening flagged something unexpected.